Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Nov 15.
Published in final edited form as: ACS Appl Bio Mater. 2021 Oct 15;4(11):7951–7960. doi: 10.1021/acsabm.1c00879

Liposomal Fe(III) Macrocyclic Complexes with Hydroxypropyl Pendants as MRI probes

Samira M Abozeid a,b, Md Saiful I Chowdhury a, Didar Asik a, Joseph A Spernyak c, Janet R Morrow a,*
PMCID: PMC9124523  NIHMSID: NIHMS1800799  PMID: 35006776

Abstract

Paramagnetic liposomes containing Fe(III) complexes were prepared by incorporation of mononuclear (Fe(L1) or Fe(L3)) or dinuclear (Fe2(L2)) coordination complexes of 1,4,7-triazacyclononane macrocycles containing 2-hydroxypropyl pendant groups. Two different types of paramagnetic liposomes were prepared. The first type, LipoA, has the mononuclear Fe(L1) complex loaded into the internal aqueous core. The second type, LipoB, has the amphiphilic Fe(L3) complex inserted into the liposomal bilayer and the internal aqueous core loaded with either Fe(L1) (LipoB1), or Fe2(L2) (LipoB2). LipoA enhances both T1 and T2 water proton relaxation rates. Treatment of LipoA with osmotic gradients to produce a non-spherical liposome produces a liposome with a chemical exchange saturation transfer (CEST) effect as shown by an asymmetry analysis, but only at high osmolarity. LipoB1, which contains an amphiphilic complex in the liposomal bilayer produced a broadened Z-spectrum upon treatment of the liposome with osmotic gradients. The r1 relaxivity of LipoB1 and LipoB2 were higher than the r1 relaxivity of LipoA on a per Fe basis, suggesting an important contribution from the amphiphilic Fe(III) center. The r1 relaxivities of paramagnetic liposomes are relatively constant over a range of magnetic field strengths (1.4 T to 9.4 T), with the ratio of r2/r1 substantially increasing at high field strength. MRI studies of LipoB1 in mice showed prolonged contrast enhancement in blood compared to the clinically employed Gd(DOTA), which was injected at 2-fold higher dose per metal than the Fe(III) loaded liposomes.

Keywords: liposome, iron coordination complexes, magnetic resonance imaging contrast agent

INTRODUCTION

Liposomes are small bilayer vesicles of typically 100 to 400 nm in size that are formed from phospholipids.13 Liposomes are commonly used to encapsulate small molecules within their hydrophilic interior core for biomedical applications such as the transport of small molecule drugs in vivo.4, 5 Liposomes have biodistribution profiles that are distinct from those of small molecules and thus may improve the pharmacokinetic profile of the drug.6 For example liposomes, as examples of nanoparticles, accumulate in tumors by the enhanced permeability retention effect.3 Moreover, targeting of liposomes to specific tissues may be enhanced by the attachment of peptides or antibodies to the lipid polar head groups.5, 7 In these studies, it is useful to track the biodistribution of the liposome and the corresponding delivery of the drug cargo by adding imaging probes to the liposome.6, 811 Such a theranostic approach is desirable to combine drug treatments with a diagnostic procedure.6, 12, 13 As for choices of diagnostic options, Magnetic Resonance Imaging (MRI) is one of the most powerful procedures used clinically, due to its unlimited depth penetration and high resolution.14, 15 A paramagnetic metal complex is added to the liposome to facilitate its tracking through MRI. Paramagnetic liposomes enhance the MR image through enhanced T1 or T2 water proton relaxation rates5, 9, 13, 16 or alternatively, by production of a chemical exchange saturation transfer (CEST) effect.17

Gd(III) complexes are the most frequently used for production of paramagnetic liposomes. Typically, an alkyl chain is added to the Gd(III) complex to incorporate it into the lipid bilayer.3, 8, 11, 17 This places Gd(III) complexes at the bulk water interface for more effective water proton relaxation. If the Gd(III) complex is anchored rigidly to the liposome through careful placement of more than one alkyl chain, enhanced T1 proton relaxation may result from a longer rotational correlation time of the Gd(III) center in the liposomal nanoparticle.18 Alternatively, the free Gd(III) complex may be encapsulated in the liposomal interior or core. In this case, the proton relaxation per Gd(III) may be quenched due to slow exchange of the water molecules through the lipid bilayer relative to the rate of proton relaxation of the water molecules surrounding the Gd(III) complex.1820

Alternatively, liposomes containing other lanthanides including Tm(III), Dy(III), Eu(III) or Yb(III) may produce a shift of the intraliposomal water proton resonances to produce a CEST effect in a process that involves exchange of the interior water molecules with the bulk water.17, 21, 22 The paramagnetic complexes in such lipoCEST agents shift the water proton resonances in the interior of the liposome away from that of the bulk water. Irradiation of the interior water protons with a presaturation radiofrequency pulse followed by exchange through the liposomal membrane leads to a CEST effect that can be used for imaging.17 LipoCEST agents have the advantage of much higher sensitivity due to the large number of intraliposomal water molecules compared to simple paraCEST agents and have been shown to produce detectable signal at nanomolar concentrations.17 While the most common choice of paramagnetic metal center for lipoCEST agents features Ln(III) with large magnetic anisotropies such as Dy(III), Yb(III) and Tm(III),8, 11, 21, 22 a transition metal lipoCEST agent has been recently reported.23 This agent contains two different high spin Co(II) complexes which produce some of the largest water proton shifts reported to date for transition metal complexes.2325 When loaded into liposomes, Co(II) complexes produce lipoCEST agents. However, even metal ions with isotropic distribution of unpaired f-electrons such as Gd(III) may produce lipoCEST agents if liposomes of oblong shapes are used.26 In this case, there is a bulk magnetic susceptibility contribution that gives rise to an additional shift of the proton resonance of the intraliposomal water. Such non-spherical liposomes are produced by treating the liposomes with an osmotic gradient. Incubation of the liposome in a solution of greater osmolarity than that on the inside results in a leakage of the water molecules from the liposome and a corresponding change in shape.22 Thus, liposomes that are core-loaded with Gd(III) complexes may behave as T1, T2 or CEST agents, a three in one probe.26

High-spin Fe(III) complexes enhance proton relaxation rates and are of interest as alternatives to Gd(III) contrast agents.2733 A potential advantage in the development of iron-based coordination complexes arises from iron’s status as the most abundant transition metal in the human body and the availability of biological pathways in humans for recycling and storage of iron.34, 35 Here we introduce some of the first examples of liposomes loaded with high spin Fe(III) macrocyclic complexes. Most other examples of iron-loaded liposomes contain superparamagnetic iron oxide nanoparticles (SPIONs).3638 An earlier example of iron coordination complexes featured deferoxamine Fe(III) derivatives loaded inside of a liposome.6 An additional early report that used a long chain derivative of DTPA (diethylenetriamine pentaacetate) to coordinate Fe(III) failed to produce stable liposomes whereas Mn(II) or Gd(III) analogs were stable.39 Our goal here was to prepare some of the first stable iron complex-based liposomes and to study both encapsulated complexes and complexes incorporated into the bilayer. Liposomes with encapsulated complex are of interest as MRI probes that respond to temperature or pH changes to release the encapsulated complex.5, 11, 40 Liposomes with paramagnetic complex incorporated into the bilayer are of interest as enhanced T1 , T2 or lipoCEST MRI probes.5, 710, 18, 39

The coordination complexes studied here are members of a new class of high spin Fe(III) complexes with macrocyclic ligands that are effective T1 MRI probes.28, 41, 42 Members of this class of compounds produce r1 relaxivity values that are comparable to Gd(III) agents in serum and show enhanced contrast in mice at 4.7 T.28 These macrocyclic complexes are part of a larger recent effort to develop Fe(III) coordination complexes as alternatives to the current clinically used Gd(III) contrast agents.27, 30 Some of the new Fe(III) contrast agents lack an exchangeable water ligand, yet still show pronounced r1 proton relaxivity through second-sphere interactions.28, 43 The better-known Fe(III) coordination complexes that are seven-coordinate and contain linear polyaminocarboxylate ligands and an exchangeable inner-sphere water ligand have been studied for many years,30, 33 however, improved derivatives have been recently reported.29, 44 Such classical Fe(III) complexes have been recently analyzed in detail through nuclear magnetic dispersion studies and theoretical calculations to elucidate contributions to proton relaxivity.45

Two different types of liposomes are studied here including LipoA with internally loaded Fe(III) coordination complex, and LipoB with internally loaded Fe(III) complex and an amphiphilic Fe(III) complex that incorporates into the bilayer.17 Two of the Fe(III) complexes lack an inner-sphere water,42 but have protons on the hydroxypropyl groups to facilitate second sphere water interactions or proton-exchange based T1 relaxation.46 The dinuclear Fe(III) complex has one bound water per iron center.41 LipoA and LipoB are studied as T1 and T2 MRI probes. The potential of these paramagnetic liposomes to produce LipoCEST agents is studied as a third contrast mechanism. The liposome with the highest r1 relaxivity per particle was chosen to study as an MRI contrast agent in mice.

EXPERIMENTAL SECTION

Instrumentation.

A Varian Inova 500 MHz NMR spectrometer (11.7 T) equipped with FTS Systems TC-84 Kinetics Air Jet Temperature Controller was used to collect 1H NMR spectra. 13C NMR spectra were acquired using a Varian Mercury 300 MHz or 400 MHz NMR spectrometer. Proton relaxivity experiments were performed at 1.4 T (34 °C) on a Nananalysis NMR spectrometer, at 4.7 T (37 °C) on a Bruker preclinical MRI scanner or at 9.4 T, (37 °C) on a Varian Inova 400 MHz NMR spectrometer. Z-spectra were collected on a Varian Inova 500 MHz NMR spectrometer (11.7 T). All pH measurements were made by utilizing an Orion 8115BNUWP Ross Ultra Semi Micro pH electrode connected to a 702 SM Titrino pH. ThermoFinnigan LCQ Advantage IonTrap LC/MS equipped with a Surveyor HPLC system was used to for mass spectrometry data of the complexes. Iron concentration was determined by using a Thermo X-Series 2 ICP-MS as reported.42, 47

Chemicals.

DPPC, DSPE-PEG2000, and cholesterol were purchased from Avanti Polar Inc. (Alabaster, Al, USA). The L1 and L2 ligands, and their iron complexes, [Fe2(L2)Cl2]Cl2 and Fe(L1)Cl2, and were prepared as reported.41, 42

Synthesis of L3.

In a 10 mL round-bottom flask, (2S,2′S)-1,1′-(1,4,7-triazonane-1,4-diyl)bis(propan-2-ol) (0.2 g, 0.82 mmol)28 was dissolved in 5.0 mL of absolute ethanol. To this solution was added racemic 2-hexadecyloxirane (1.22 mmol, 1.5 equiv). After the solution was stirred at 60 °C for 3 days, the solvent was removed under pressure to yield a pale-yellow powder. The crude product was then dissolved in methanol or ethanol, and any precipitate was removed by filtration. The filtrate was dried under reduced pressure to yield (2S,2′S)-1,1′-(7-(2-hydroxyoctadecyl)-1,4,7-triazonane-1,4-diyl)bis(propan-2-ol) with 80% yield. ESI-MS: m/z 514.50 (M+H+, 100%) where M = L3. 1H NMR: (400 MHz, CDCl3): δ 4.40 (3H, -OH), δ 2.61, 2.58 (6H, -CH2-NH- hydroxylpropyl pendants), δ 3.76,3.52 (3H, -CH alcohol pendent), δ 2.79, 2.65 (12H, -CH2 macrocycle), δ 1.08 (6H, -CH3) and δ 0.87, 1.25, 1.24 (protons of two long chain carbon). 13C NMR (300 MHz, CDCl3): δ 14.08, 22.68 (3C, -CH3), δ 51.01 (6C, macrocycle ring), δ 74.92, 70.34 (3C, -CH alcohol pendent), δ 67.34, 64.61 (3C, -CH2-NH- alcohol pendents), and δ 37.81, 33.14, 31.91, 29.67, 29.35, 25.53 (15C, -CH2 long chain carbon).

The Fe(L3) complex was synthesized by dissolving L3 (0.15 mmol) in ethanol and heating the solution to 60°C. Iron(II) chloride (1-2 equivalents) was dissolved in ethanol (2.0 mL) and was added dropwise to the ethanolic ligand solution in which the product precipitated as a yellow solid. The solution was allowed to stir overnight, then filtered and the product was washed with ethanol. The [Fe(L3-H+)]Cl complex was isolated as a brownish-orange solid in 55% yield. ESI-MS of [Fe(L3-H+)]Cl: m/z = 567.4 [M+] 589.5 [M+Na+] and 1155 [2M+Na+]. Percent iron through ICP-MS analysis: 94%. Here M+ is [Fe(L3-2H+)].

Magnetic susceptibility.

The effective magnetic moments (μeff,) of the complexes or paramagnetic liposomes were determined by 1H NMR by using the Evans method.48, 49 Samples were prepared using a coaxial NMR insert which contained the diamagnetic standard of 5 % t-butanol in D2O. Evans method was used to determine the effective magnetic moment of Fe(III) complexes and as a way to determine the concentration of Fe(III) complexes in the liposomes as reported previously for Co(II) loaded liposomes.23

Liposomes preparation and characterization.

Liposome Type A (LipoA) was prepared using the previously reported ethanol injection method with some modifications.23 The hydration solution was 40-50 mM of Fe(III) complex, pH 6.8-7.2, adjusted using meglumine solution and total lipid content was 20 mg/mL. The bilayer was composed of DPPC/Cholesterol/DSPE-PEG2000 with a molar ratio of 55:40:5. To reduce the size, the liposome suspension was passed 12 times at 60 °C through sequentially stacked polycarbonate membranes of 100 nm and 6 times through 80 nm pore size using an Avanti mini-extruder with heating block. Non-encapsulated complex was eliminated by exhaustive dialysis at 4 °C. Shrunken liposomes were prepared by dialysis against different concentrations of HEPES/NaCl buffer pH 7-7.2. The Fe concentration was determined by using ICP-MS and/or NMR spectroscopy by measuring bulk magnetic susceptibility (Evans Method).48

Liposome type B (LipoB) was prepared using the liposomal formulation of DPPC/DSPE-PEG2000/Cholesterol/Amphiphilic Fe(L3) (molar ratio of 54:6:30:10). LipoB was made by dissolving the lipid mixture in chloroform/methanol, then evaporating the solution to dryness under vacuum to produce thin lipid film formation. The thin film was hydrated with an aqueous solution (1 mL) containing 50 mM of the hydrophilic complex; Fe(L1) or Fe2(L2) at 50 °C. The pH of the iron complex containing solution was raised to the desired pH by adding meglumine. The solution was stirred for 90 minutes at 50 °C followed by stirring at 25 °C for 90 minutes. The liposome suspension was then extruded to reduce the size by passing 20 times through polycarbonate membranes of 200 nm using the Avanti mini extruder with the heating block. To remove any free complex, the liposome suspension was dialyzed against 300 mOsm/L of NaCl aqueous solution and HEPES buffer pH 6.8-7.2 at 4° C. Alternatively, the liposomes were isolated and washed by using ultrafiltration. The liposomal suspension was washed with 300 mOsm/L of NaCl aqueous solution using Amicon 100 KDa ultra-filtration kit. The first filtrate was saved to calculate the entrapped iron complex inside liposomal core using UV-vis spectroscopy. In these studies, the electronic absorbance of Fe(L1) filtrate at 330 nm was compared to that of aqueous Fe(L1) solution42 for thin film hydration during liposome formulation. The liposomal solution was then sequentially washed five more times using the same ultra-centrifugal filtration kit to remove free Fe(L1) complex. The mean hydrodynamic liposome diameter was determined by dynamic light scattering. The iron content was determined by ICP-MS. All liposomes were stored at 4 °C.

Water proton relaxation time measurements.

Experiments were performed at several magnetic field strengths including 1.4 T (34 °C), 4.7 T (37 °C) or at 9.4 T, (37 °C). Several different concentrations were prepared by diluting either iron complexes (non-liposomal system) or liposomes, then the sample was placed into a coaxial tube insert and placed in an NMR tube filled with DMSO-d6. The T1 proton relaxation measurement was run on liposomes in the absence of the paramagnetic complexes as well. The T1 proton relaxation times of solutions containing complex or liposomes were measured on a 9.7 T NMR spectrometer at 37 °C using the inversion recovery method with the following parameters: relaxation delay = 15-20 s, echo time array starting from 0.2–5 s, and a receiver bandwidth = 28 ms. T2 relaxation times were measured using the Carr–Purcell–Meiboom–Gill (CPMG) spin echo method. The CPMG sequence was used with a fixed TR of 10 s and TE times ranging from 0.02–4 ms in 0.1 s increments.

Z-spectra.

In general, the Z-spectra of shrunken liposomes were acquired at 37 °C at 11.7 T with varied pre-saturation pulse power (B1) applied for 2 seconds, and the frequency offset was varied in either 500 or 250 Hz increments. The Z-spectrum was obtained by plotting normalized water intensity against offset frequency. The aqueous liposome sample was placed into a coaxial tube insert, within an NMR tube filled with DMSO-d6.

Mice imaging studies.

MR imaging studies with the Fe(III)-based liposomes and complexes were studied on at 4.7 T Bruker preclinical MRI in healthy mice (BALB/cJ, Jackson Laboratory). Solutions were formulated with Fe(III) complex loaded liposomes at 20 mg lipids/mL. To study enhancement kinetics, serial T1-weighted, 3D, spoiled-gradient echo scans (TE/TR = 3/15ms, flip angle = 40°) covering the mouse from thorax to tail were acquired prior to and after administration of compounds. NMR tubes loaded with 1% agarose doped with CuSO4 were used for MRI signal normalization. Animals were dosed with 25 μmol [Fe]/ kg intravenously via tail vein and MR data were recorded continuously for up to 1 hour, and additionally at 4 hours post-administration. For comparison, FDA-approved MRI contrast agent gadoterate meglumine (Gd-DOTA, Dotarem®) was injected at 50 μmol [Gd]/kg into a separate group of mice. Signal intensities were normalized to the phantoms, and signal increase in each organ was measured. Studies were carried out in triplicate (n=3) for each compound tested.

RESULTS AND DISCUSSION

The development of Fe(III) complexes that are of sufficient solubility for liposome encapsulation, typically 40-100 mM, in aqueous solution is a challenge. Moreover, the slow kinetics of ligand exchange involved in the formation of Fe(III) complexes makes it difficult to obtain complexes by adding Fe(III) salts to already prepared liposomes. For example, previous research that failed to form stable liposomes containing an amphiphilic Fe(III) DTPA derivative in water added Fe(III) salts in the last step.39 In studies here, the Fe(III) complexes are formed first and then incorporated into the liposomes. The complex aqueous solution chemistry of Fe(III) may also be problematic as complexes with a bound water may undergo dimerization to produce a u-oxo bridged dimers.44 For this reason, we chose to use Fe(III) complexes of the 1,4,7-triazacyclononane (TACN) macrocycle. The complexes contain hydroxypropyl pendants to stabilize the iron center as high spin Fe(III). In complexes with open coordination sites, the hydroxypropyl pendants inhibit dimerization and produce complexes of moderately high solubility in water.28 This class of complexes is inert towards dissociation in the presence of physiologically relevant concentrations of phosphate and carbonate or in solutions containing 100 mM HCl, at 37 °C over a period of several hours to days.41, 42

The Fe(L1) and Fe(L3) complexes are six-coordinate and lack an inner-sphere water ligand, whereas the dinuclear complex (Fe2(L2)) has a coordination site for bound water on each Fe(III) center.41, 42 The proton r1 relaxivity of Fe(L1) is attributed predominately to second-sphere and outer-sphere water interactions (Table 1, Figure S1).42, 46 Notably, the dinuclear Fe(III) complex has a 2.6-fold greater relaxivity per molecule compared to Fe(L1) at 4.7 T. The greater relaxivity of the Fe(III) centers of the dinuclear complex is attributed to the open coordination sites that allow for an inner-sphere water molecule. Notably, the exchange of the inner-sphere water on Fe2(L2) is slow on the NMR time scale, yet the complex still produces higher relaxivity than complexes that lack the bound water.41 The r1 relaxivity of the dinuclear complex is also expected to be larger than the mononuclear complex due slower tumbling times and by the presence of two Fe(III) centers. Fe(L3) contains a long alkyl chain to give an amphiphilic complex for incorporation into the liposomal bilayer. Notably, all complexes are cationic at neutral pH (Scheme 1) as determined by studies using pH-potentiometric titrations.28, 41, 42

Table 1.

The r1 and r2 relaxivity values for liposomes and complexes at 4.7, 9.4 T (37 °C) and 1.4 T (34 °C) and pH 6.8-7.2.

AGENT r1(mM−1s−1) 1.4 T r1(mM−1s−1) 4.7 T r1(mM−1s−1) 9.4 T r2(mM−1s−1) 1.4 T r2(mM−1s−1) 4.7 T r2(mM−1s−1) 9.4 T
Fe(L1) a 1.5 ± 0.2 0.97± 0.12 1.4± 0.1 - 1.8± 0.5 -
Fe2(L2) b 3.5± 0.3 5.3± 0.1 4.0 ± 0.3 - 13.0± 0.2 -
LipoA c 0.84± 0.15 0.92± 0.20 1.2± 0.1 2.0± 0.2 1.6± 0.3 8.7± 1.0
LipoB1 1.7 ± 0.3 1.7± 0.4 2.1± 0.2 2.8± 0.3 9.4± 0.9 20 ± 3
a.

Data at 1.4 and 4.7 T from references.42, 46

b.

from reference.41

c.

for liposomes of 126 nm size.

Scheme 1.

Scheme 1.

Schematic of LipoA and LipoB. The predominant Fe(III) complex species in this study are shown in their protonation state at neutral pH.

LipoA studies.

The first type of liposome studied, LipoA, was prepared by encapsulating Fe(L1) into the liposomal interior. The hydration solution contained 40-50 mM of Fe(III) complex, pH 6.8-7.2 and total lipid content was 20 mg/mL. The bilayer was composed of DPPC/Cholesterol/DSPE-PEG2000 with a molar ratio of 55:40:5. PEGylated liposomes were used to prevent vesicle aggregation50 and to increase the blood circulation time by decreasing the extent elimination through the hepatobiliary system in mice.2, 5, 51 The relatively high percentage of cholesterol was used to reduce PEG chain interactions52 and to modulate the water exchange rate constants.53 The total Fe(III) content was determined by ICP-MS of liposomes and filtrate and by measurement of magnetic susceptibility by using the Evans method.21, 48 Despite the high concentration of complex used to make the liposomes, the concentration of the complex inside the liposomes ranged from 8-10 mM Fe(L1).

The T1 proton relaxation times of the LipoA liposomes were measured as a function of liposomal size for three different sizes. The r1 relaxivity decreased as the liposome size increased ranging from 0.50 mM−1s−1 to 1.0 mM−1s−1 (Table S2, Figure S2), consistent with the expected decrease in surface/volume ratio for larger liposomes. Larger surface to volume ratios of small liposomes favor higher rates of water exchange between the intraliposomal and extraliposomal water molecules.54 Thus, the quenching of r1 relaxivity observed for larger-sized LipoA (208 and 380 nm), is attributed to slowed water exchange through the lipid bilayer compared to the proton water relaxation rate of free complex.55 By comparison, the r1 relaxivity of the free Fe(L1) complex at 1.5 mM−1s−1 at 1.4 T, 34 °C was higher than that for any of the LipoA formulations on a per iron basis.

The magnetic field strength dependence of the r1 relaxivity of LipoA shows a 20 % increase on going from 1.4 T to 4.7 T, but little change at higher field strengths. This trend is similar to that observed for simple coordination complexes of Fe(III). Unlike Gd(III) complexes, Fe(III) macrocyclic complexes do not show the trend of decreasing relaxivity at high field strengths.41 Full field strength dependence in the form of nuclear magnetic dispersion (NMRD) studies on iron coordination complexes are scarce, but increasing interest in Fe(III) contrast agents has brought renewed effort in this endeavor.45, 56, 57 An explanation for the trend for Fe(III) complexes is that the relatively fast electronic relaxation times of the Fe(III) centers are better suited for the higher field strengths that are studied here.58 On the other hand, the r2 relaxivity of LipoA increases substantially at 9.4 T. The increase of r2 relaxivity with field strength is predicated on the large field strength dependence of the magnetic susceptibility contribution to r2.9 Thus the r2/r1 ratio increases from 2.3 at 1.4 T to 7.3 at 9.4 T for LipoA.

LipoA was also studied as a lipoCEST agent by recording the Z-spectra as shown in Figure 1. LipoCEST agents have intraliposomal water proton resonances that are shifted from that of bulk water by the paramagnetic complexes trapped in the interior of the liposome.17 For metal ions with magnetic anisotropy arising from the asymmetrical distribution of electrons in the d or f orbitals, such as Co(II) or Tm(III), respectively, the intraliposomal water proton shift is a result of the hyperfine contribution which arises from to the interaction between the intraliposomal water protons and the paramagnetic center.21 In contrast, metal ions with an isotropic distribution of electrons including high spin Fe(III) complexes or Gd(III) complexes are not expected to produce a hyperfine shift of the water protons in spherical liposomes. However, a liposome loaded with a paramagnetic complex which is not spherical, but is oblong in shape, is expected to have a bulk magnetic susceptibility contribution (Eq. 1). Here ∆intraliposomal is the chemical shift difference between intraliposomal and bulk water protons, ∆Hyp is the contribution from the hyperfine shift of the paramagnetic complex and ∆BMS is the bulk magnetic susceptibility shift. Thus, Gd(III) complexes in non-spherical liposomes have been shown to shift the water proton resonances away from that of bulk water and to exhibit a lipoCEST effect.26 Similarly, high spin Fe(III) as an isotropic metal ion would be expected to show a negligible CEST effect when loaded in a symmetrical liposome, but potentially exhibit a CEST effect in an oblong shaped liposome.22

ΔIntralipo=ΔHYP+ΔBMS Eq. 1

Figure 1:

Figure 1:

Z-spectrum of LipoA, which is core loaded with Fe(L1), at 1200 mOsm/L, at 37 °C, pH 6.8, 11.7 T.

Shrinkage of the Fe(III)-based LipoA produced a Z-spectrum with a shoulder at about 5ppm as presented in Figure 1 and Figures S3S5. Shrunken liposomes were prepared by applying osmotic stress through dialysing the liposome suspension against different concentrations of NaCl and HEPES buffer to change the shape of the liposome from spherical to oblong.21, 59 The shoulder on the Z-spectrum was pronounced only at high osmotic stress (600-1200 mOsm/L), which is larger than that found under physiological conditions (300 mOsm/L). Given the small difference between the bulk water proton resonance and the intraliposomal water proton resonance ∆ω, the magnetization transfer asymmetry (MTRasym) profile was plotted in Figure S5 to better analyze the effect.60 The small frequency offset centered at 4 ppm associated with the MTRasym plot is attributed to the low concentration of Fe(III) complex and to the isotropic state of the Fe(III) ion. Gd(III) loaded liposomes similarly showed small intraliposomal water proton shifts (7 ppm at 300 mOsm/L) that were not as large as that of other lanthanide shift agents.26 The frequency offset for the CEST shoulder that we observe here for Fe(III) loaded liposomes is also less than that observed with Co(II) loaded liposomes, as an additional example of a transition metal probe. Co(II) macrocyclic complexes are effective water proton shift agents and produce a LipoCEST peak at about 10 ppm with complexes loaded into the liposome interior.23

LipoB studies.

To enhance the relaxivity of the iron liposomes, an amphiphilic iron complex was added to the bilayer while keeping the liposomal interior filled with complex. We anticipated that LipoB agents would have a large per particle relaxivity with the two different types of Fe(III) complexes. LipoB was prepared with Fe(L3) as an amphiphilic agent inserted in the liposomal bilayer and with the aqueous cavity (lumen) loaded with either Fe(L1) complex (LipoB1) or with Fe2(L2) (LipoB2). A liposomal formulation comprised of 40 mM total lipid - DPPC/DSPE-PEG2000/Cholesterol/Amphiphilic Fe(L3) (molar ratio of 54:6:30:10) was used, which is similar to that of LipoA, but with the addition of the amphiphilic complex. LipoB was made by dissolving the lipid mixture in chloroform/methanol, then evaporating the solution to dryness under vacuum to produce thin lipid film formation. The thin film was hydrated with an aqueous solution (1 mL) containing 50 mM of the hydrophilic complex; Fe(L1) or Fe2(L2) at 50 °C. The sizes of LipoB1 and LipoB2 were 190 nm and 180 nm, respectively as measured by dynamic light scattering. The overall iron content was determined by ICP-MS and showed that there was almost three-fold more iron per liposome in LipoB2 than in LipoB1. Calculations of iron per liposome particle give the equivalent of 12 mM iron for LipoB1 and 30 mM iron for LipoB2, which includes both the internal and the liposomal surface Fe(III) content. Assuming that the lipid bilayer in both LipoB1 and LipoB2 contains the 10% of amphiphilic Fe(III) complex, the higher concentration of iron in LipoB2 suggests that a higher loading efficiency is obtained with the dinuclear complex. A higher loading efficiency was observed previously for liposome containing multinuclear lanthanide complexes17, 61, 62 and suggests that this method will be successful for Fe(III) complexes as well.

The proton relaxivity of the paramagnetic liposomes (LipoB) has three contributions including from iron centers in the external liposomal layer (Cout), and Cin which corresponds to the concentration of iron centers embedded in the internal layer that directly interact with the intraliposomal water protons. In addition, there is the internal component which is related to the amount of hydrophilic agent in the liposomal internal aqueous cavity. If the water exchange rate through the liposomal membrane is sufficiently rapid, the overall r1 relaxivity has contributions from Cin, Cout and Cinternal.20 Despite the fact that the relaxivity of Fe2(L2) per molecule was higher (4.9 mM−1s−1 at 9.4T, and 5.3 mM−1s−1 at 4.7T in Table 1) than the relaxivity of Fe(L1) complexes (0.97 mM−1s−1 at 4.7 T or 1.4 mM−1s−1 at 9.4 T), loading the liposomes with these hydrophilic complexes produced liposomes with similar relaxivities for lipoB1 and lipoB2 on a per Fe basis at 2.0 (± 0.3) and 1.9 (± 0.3) mM−1 s−1 at 9.4 T for LipoB1 and lipoB2, respectively. The similarity of these r1 relaxivity values is consistent with quenching of relaxation of intraliposomal water protons through compartmentalization effects. Such quenching has been observed for Gd(III) complexes, especially at high concentrations of contrast agent.55 This data also supports a major contribution to the relaxivity in both LipoB1 and LipoB2 from the Fe(III) centers present in the external liposomal layer which interact directly with the bulk water protons.19, 20

The larger r1 relaxivity of LipoB1 and LipoB2 compared to LipoA is attributed to more effective extraliposomal water proton relaxation by amphiphilic Fe(III) centers. Moreover, the amphiphilic Fe(III) center is anticipated to have improved T1 proton relaxation based on a longer rotational correlation time as it is incorporated into a large liposomal particle. The per particle r1 relaxivity of the iron-based liposomes showed the (Figure S6) at 9,000 mM−1s−1 and 34,000 mM−1s−1 for LipoA and LipoB1 respectively. The nearly 4-fold larger r1 relaxivity per particle for LipoB1 shows the advantage of loading liposomal core and lipid bilayer with Fe(III) complexes.

Additional studies were carried out with LipoB1 as an example of a dual-mode liposome with Fe(III) complex loaded into the liposomal interior and also the bilayer. The r1 proton relaxivity of LipoB1 shows a slight increase in r1 relaxivity with increasing field strength, like that observed for LipoA. In contrast, the r2 relaxivity shows a more pronounced jump between 4.7 and 9.4 T (Table 1) as expected from the more pronounced effect of field strength on T2 processes which is related to susceptibility contributions.9 The relaxivity of LipoB1, like LipoA, did not change markedly over the period of three days, supporting a relatively stable liposomal formulation (Figure S7).

LipoB1 was treated with high osmolarity solutions (1200 mOsm/L) and the Z-spectrum was recorded. Unlike LipoA where there was a distinct shoulder in the Z-spectrum, the Z-spectrum of lipoB1 did not show a pronounced shoulder. However, a plot of the magnetization transfer asymmetry shows a peak at a frequency offset of 4 ppm (Figure S5). The broadening of the Z-spectrum for LipoB1 is attributed to the increased T2 effect of the amphiphilic Fe(III) complexes in the lipid bilayer. Moreover, the Fe(III) complexes that are incorporated into the liposome are expected to mask the CEST effect through T1 proton relaxation. For example, conjugation of a Gd(III) complex to the external surface of a LipoCEST agent serves to quench the CEST effect.63

Effect of pH, temperature and serum proteins.

In mouse serum, the r1 relaxivity values of both LipoA and LipoB1 at 1.4 T increase modestly. For LipoA, the r1 relaxivity increases from 1.0 to 1.7 mM−1s−1 (Figure S8) whereas for LipoB1 the change is from 1.7 to 2.3 mM−1s−1. This increase in relaxivity is most consistent with association of the liposomes and serum proteins. Incubation of LipoB1 with serum over a three-day period shows only small changes in relaxivity, suggesting that the liposomes remain largely intact in blood serum (Figure S9). By comparison, the proton relaxivity of free Fe(L1) complex shows little change in the presence of serum albumin consistent with only very weak interactions.42

The effect of temperature and pH on the relaxivity of iron-based liposomes was studied to further characterize the physical properties of the liposomes and towards applications as responsive agents. The change in relaxivity of the liposomes (LipoA and LipoB1) with pH and temperature is shown in Figure 2 and Figure S10, respectively. The Fe(III) complexes in these liposome formulations contain no inner-sphere water, so proton relaxation is mediated by second-sphere waters or, alternatively, by proton exchange.42 The decrease in r1 relaxivity with increasing pH for LipoB1 is consistent with acid catalyzed proton exchange contributions of the hydroxypropyl groups on the exterior of the liposome. Such proton exchange contributions to relaxivity have been observed for Gd(III) complexes with hydroxy pendants64 and for Fe(III) aquo complex.45 A liposome-based Gd(III) system reported previously showed a pronounced increase of the water proton relaxation rates at acidic pH.65 For LipoA, the proton relaxivity also increases with a decrease in pH but the shape of the pH profile is convex. This profile suggests that there are additional contributing factors such as a pH dependence of the water exchange through the liposome.

Figure 2.

Figure 2.

Plots of proton relaxation rate constants as a function of pH recorded for LipoA (Left) and LipoB1 (Right), at 34 °C, 1.4 T.

A modest temperature dependence is observed for both LipoA and LipoB1 (Figure S10). For both LipoA and LipoB, the r1 relaxivity decreases with temperature from 24 °C to 45 °C or 50 °C, respectively. This is similar to the decrease in relaxivity with an increase in temperature that is observed for Fe(L1) and for other closed-coordination sphere Fe(III) complexes.46 Such a decrease with increasing temperature is attributed to decreasing correlation times from rotational motion and the electronic relaxation time of the Fe(III) center.66 However, at higher temperatures (>45°C for LipoA and > 50°C for LipoB1), the r1 relaxivity increases with temperature. This increase suggests greater bilayer permeability to water and more rapid water exchange.19 Cycling studies are consist with the liposome remaining largely intact at these temperatures. The relaxivity at 37°C is only slightly increased compared to initial studies as the temperature is brought back down (Figure S6). This result suggests that the enhancement in the relaxivity as temperature is increased is predominantly due to increasing the exchange rate between the extraliposomal and intraliposomal water molecules from increased liposomal membrane permeability at high temperatures.

Mice Imaging.

PEGylated liposomes have a long circulation time in animals,16 with PEGylation being key to resisting rapid sequestration by hepatobiliary elimination pathway and are important in drug delivery by liposomes. Gd-labeled PEGylated liposomes remain in the vasculature and show enhanced MRI contrast as blood pool agents. To gauge whether our iron-based liposomes would show similar characteristics in animals, LipoB1 was chosen for study to capitalize on its high per particle r1 relaxivity. Comparison was made to Gd(DOTA). Both agents were studied in BALB/cJ mice on a small animal 4.7 T MRI scanner upon tail vein injection of the agent. The injected lipid dose was 200 mg/kg, which corresponds to 0.025 mmol iron/kg, compared to 0.05 mmol Gd(DOTA)/kg. Biodistribution and pharmacokinetic clearance of the agents in mice were monitored by MRI and are shown in Figures 34.

Figure 3.

Figure 3.

Changes in T1-weighted signal intensities for LipoB1 (25 μmol [Fe]/kg versus Gd-DOTA 50 μmol[Gd]/kg over time in four different regions; blood (vena cava), kidneys, liver and urinary bladder in healthy BALB/cJ mice.

Figure 4.

Figure 4.

Changes in T1-weighted signal intensities up to 4 h post injection for LipoB1 in tissues in healthy BALB/cJ mice at 4.7 T, at 200 mg lipids/kg. Residual enhancement in all tissues except liver was observed at 4 hours, indicating extended circulation.

MR imaging shows longer retention and higher signal in the Vena Cava for LipoB1 compared to Gd(DOTA) complex as expected for a blood pool agent (Figure 3). The intensity of the signal with the iron liposomal agent compares favorably to that of Gd(DOTA), given the 2-fold lower amount injected in comparison to the Gd(III) complex. There is sustained uptake into the liver, but little gall bladder enhancement, suggesting that mostly renal clearance. This clearance differs from that shown for paramagnetic liposomes that are not surface functionalized. Non-pegylated liposomes appear predominantly in the liver.2, 39 MR images for the experiments with LipoB1 are shown in Figure S14.

It is worth noting that the LipoB1 formulation studied here was stable in solutions containing serum for three days. However, we cannot rule out disruption of the liposome in the animal. Disruption of the phospholipid bilayer in LipoB1 would release some of the iron complexes from the interior to enhance contrast in the urinary bladder. Further studies are required to investigate this possibility. Nonetheless, initial studies are encouraging as they show enhanced and prolonged contrast of a blood vessel and predominantly renal clearance.

CONCLUSIONS

The iron-based LipoA and LipoB liposomes feature distinct MRI probe characteristics. The LipoA agents are among the first transition metal complex-based liposomes that show both T1 and T2 proton relaxation enhancement as well as a modest LipoCEST effect in non-spherical liposomes. The r1 relaxivity per iron in LipoA was quenched compared to the Fe(III) complex in the absence of liposomes, consistent with limiting water exchange rates.55 In LipoB1 and LipoB2, the relaxivity was increased as compared to LipoA and to Fe(III) complex alone and had a much higher per particle relaxivity. This was expected based on the incorporation of an amphiphilic Fe(III) center for more effective interaction with bulk water. However, these iron-based liposomes are not as effective in proton relaxation as the best Gd(III) liposomes.18, 67 Certainly, there is room for improvement through the incorporation of Fe(III) complexes of higher relaxivity and by variation of the amphiphilic linker as discussed below. The Fe(III) centers that are present in the external layer of LipoB produce broadened Z-spectra and also contribute to a larger T2 proton relaxation effect, similar to studies of Ln(III) based liposomes. As a result, LipoA type formulations might serve as T1 MRI probes whereas LipoB1 formulations might serve as T1 or T2 MRI probes

There are several challenges we face in further developing these liposomal iron-based agents. The first challenge is to accomplish higher loading efficiency of the complexes in the liposome interior through changes in charge and lipophilicity. The use of multinuclear complexes, as shown here, is promising for increased loading. Complexes of neutral overall charge would be anticipated to give increased liposomal loading. Higher loading efficiency would benefit studies that have the goal of releasing metal complex in response to a stimulus such as pH or temperature or for lipoCEST agents.11, 68 Second, it is important to develop amphiphilic complexes that better anchor into the bilayer for effective interaction with bulk water. 69 This might be accomplished by using more than one alkyl chain and by restricting the Fe(III) coordination complex to better interact with bulk water molecules in strategies similar to those published for Gd(III) complexes.10, 18 Finally, there are other liposomal properties to vary for optimization of lipoCEST. For example, the exchange rate constant for intraliposomal water to bulk water (kex) is modulated by the composition of the liposome and may be tuned to optimize lipoCEST.53 Moreover, the shape of the Z-spectrum, and corresponding MTRasym profile depend on the magnitude of kex which varies with size of the liposome.60

Imaging studies of LipoB1 suggest that these liposomes hold promise as iron-based MRI probes that show blood pool agent characteristics. Steady-state enhancement of liver indicates some sequestration in the liver, perhaps due to the relatively large liposomal size, although most clearance is through a renal pathway. Further studies will investigate the role of different liposome compositions for in vivo biodistribution and pharmacokinetic clearance.

Supplementary Material

Supplementary Material

ACKNOWLEGMENTS

JRM acknowledges the NSF (CHE-1710224) for support of this work. JAS is partially supported by Roswell Park’s NIH P30 grant (CA016056). The authors would like to thank the Chemistry Instrument Center (CIC), University at Buffalo. This work utilized ICP-MS and FTMS that was purchased with funding from a NSF Major Research Instrumentation Program (NSF CHE-0959565) and National Institutes of Health (S10 RR029517). We thank Hailey Khilian for initial studies on liposomes.

Footnotes

Supporting Information

The Supporting Information is available free of charge at:

Notes. JRM is a co-founder of Ferric Contrast, Inc. which develops iron-based MRI contrast agents.

REFERENCES

  • 1.Guyon L; Groo AC; Malzert-Freon A, Relevant Physicochemical Methods to Functionalize, Purify, and Characterize Surface-Decorated Lipid-Based Nanocarriers. Mol Pharmaceut 2021, 18 (1), 44–64. [DOI] [PubMed] [Google Scholar]
  • 2.Ishida T; Harashima H; Kiwada H, Liposome clearance. Bioscience Rep 2002, 22 (2), 197–224. [DOI] [PubMed] [Google Scholar]
  • 3.Crich SG; Terreno E; Aime S, Nano-sized and other improved reporters for magnetic resonance imaging of angiogenesis. Adv Drug Deliver Rev 2017, 119, 61–72. [DOI] [PubMed] [Google Scholar]
  • 4.Finbloom JA; Sousa F; Stevens MM; Desai TA, Engineering the drug carrier biointerface to overcome biological barriers to drug delivery. Adv Drug Deliver Rev 2020, 167, 89–108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Langereis S; Geelen T; Grull H; Strijkers GJ; Nicolay K, Paramagnetic liposomes for molecular MRI and MRI-guided drug delivery. NMR Biomed 2013, 26 (9), 1195–1195. [DOI] [PubMed] [Google Scholar]
  • 6.Kneepkens E; Fernandes A; Nicolay K; Grull H, Iron(III)-Based Magnetic Resonance-Imageable Liposomal T1 Contrast Agent for Monitoring Temperature-Induced Image-Guided Drug Delivery. Invest Radiol 2016, 51 (11), 735–745. [DOI] [PubMed] [Google Scholar]
  • 7.Mulder WJM; Strijkers GJ; van Tilborg GAF; Griffioen AW; Nicolay K, Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006, 19 (1), 142–164. [DOI] [PubMed] [Google Scholar]
  • 8.Castelli DD; Terreno E; Cabella C; Chaabane L; Lanzardo S; Tei L; Visigalli M; Aime S, Evidence for in vivo macrophage mediated tumor uptake of paramagnetic/fluorescent liposomes. NMR Biomed 2009, 22 (10), 1084–1092. [DOI] [PubMed] [Google Scholar]
  • 9.Mulas G; Ferrauto G; Dastru W; Anedda R; Aime S; Terreno E, Insights on the relaxation of liposomes encapsulating paramagnetic Ln-based complexes. Magn Reson Med 2015, 74 (2), 468–473. [DOI] [PubMed] [Google Scholar]
  • 10.Mulas G; Rolla GA; Geraldes CFGC; Starmans LWE; Botta M; Terreno E; Tei L, Mn(II)-Based Lipidic Nanovesicles as High-Efficiency MRI Probes (vol 3, pg 2401, 2020). Acs Appl Bio Mater 2020, 3 (6), 3924–3924. [Google Scholar]
  • 11.Castelli DD; Boffa C; Giustetto P; Terreno E; Aime S, Design and testing of paramagnetic liposome-based CEST agents for MRI visualization of payload release on pH-induced and ultrasound stimulation. J Biol Inorg Chem 2014, 19 (2), 207–214. [DOI] [PubMed] [Google Scholar]
  • 12.Zhang SQ; Cheruku RR; Dukh M; Tabaczynski W; Patel NJ; White WH; Missert JR; Spernyak JA; Pandey RK, The Structures of Gd(III) Chelates Conjugated at the Periphery of 3-(1′-Hexyloxy)ethyl-3-devinylpyropheophorbide-a (HPPH) Have a Significant Impact on the Imaging and Therapy of Cancer. Chemmedchem 2020, 15 (21), 2058–2070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kamaly N; Kalber T; Ahmad A; Oliver MH; So PW; Herlihy AH; Bell JD; Jorgensen MR; Miller AD, Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. Bioconjug Chem 2008, 19 (1), 118–129. [DOI] [PubMed] [Google Scholar]
  • 14.Wahsner J; Gale EM; Rodriguez-Rodriguez A; Caravan P, Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. Chem Rev 2019, 119 (2), 957–1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Doan B-T; Meme S; Beloeil J-C, General Principles of MRI. In The Chemistry of Contrast Agenst in Medical Magnetic Resonance Imaging, Merbach A; Helm L; Toth I, Eds. Wiley: West Sussex, UK, 2013; pp 1–24. [Google Scholar]
  • 16.Ghaghada KB; Ravoori M; Sabapathy D; Bankson J; Kundra V; Annapragada A, New Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging. Plos One 2009, 4 (10) e7628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Castelli DD; Terreno E; Longo D; Aime S, Nanoparticle-based chemical exchange saturation transfer (CEST) agents. NMR Biomed 2013, 26 (7), 839–49. [DOI] [PubMed] [Google Scholar]
  • 18.Kielar F; Tei L; Terreno E; Botta M, Large Relaxivity Enhancement of Paramagnetic Lipid Nanoparticles by Restricting the Local Motions of the Gd-III Chelates. J Am Chem Soc 2010, 132 (23), 7836–7837. [DOI] [PubMed] [Google Scholar]
  • 19.Fossheim SL; Fahlvik AK; Klaveness J; Muller RN, Paramagnetic liposomes as MRI contrast agents: Influence of liposomal physicochemical properties on the in vitro relaxivity. Magn Reson Imaging 1999, 17 (1), 83–89. [DOI] [PubMed] [Google Scholar]
  • 20.Laurent S; Elst LV; Thirifays C; Muller RN, Paramagnetic liposomes: inner versus outer membrane relaxivity of DPPC liposomes incorporating lipophilic gadolinium complexes. Langmuir 2008, 24 (8), 4347–51. [DOI] [PubMed] [Google Scholar]
  • 21.Terreno E; Cabella C; Carrera C; delli castelli D; Mazzon R; Rollet S; Stancanello J; Visigalli M; Aime S, From Spherical to Osmotically Shrunken Paramagnetic Liposomes: An Improved Generation of LIPOCEST MRI Agents with Highly Shifted Water Protons. Angew. Chem. Int. Ed 2007. 46, 966–8. [DOI] [PubMed] [Google Scholar]
  • 22.Terreno E; Castelli DD; Violante E; Sanders HMHF; Sommerdijk NAJM; Aime S, Osmotically Shrunken LIPOCEST Agents: An Innovative Class of Magnetic Resonance Imaging Contrast Media Based on Chemical Exchange Saturation Transfer. Chem-Eur J 2009, 15 (6), 1440–1448. [DOI] [PubMed] [Google Scholar]
  • 23.Abozeid SM; Asik D; Sokolow GE; Lovell JF; Nazarenko AY; Morrow JR, CoII Complexes as Liposomal CEST Agents. Angew. Chem. Int. Ed 2020, 132 (29), 12191–12195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Abozeid SM; Snyder EM; Tittiris TY; Steuerwald CM; Nazarenko AY; Morrow JR, Inner-sphere and outer-sphere water interactions in Co (II) paraCEST agents. Inorg Chem 2018, 57 (4), 2085–2095. [DOI] [PubMed] [Google Scholar]
  • 25.Bond CJ; Sokolow GE; Crawley MR; Burns PJ; Cox JM; Mayilmurugan R; Morrow JR, Exploring inner-sphere water interactions of Fe (II) and Co (II) complexes of 12-membered macrocycles to develop CEST MRI probes. Inorg Chem 2019, 58 (13), 8710–8719. [DOI] [PubMed] [Google Scholar]
  • 26.Aime S; Castelli DD; Lawson D; Terreno E, Gd-loaded liposomes as T-1, susceptibility, and CEST agents, all in one. J Am Chem Soc 2007, 129 (9), 2430-+. [DOI] [PubMed] [Google Scholar]
  • 27.Gupta A; Caravan P; Price WS; Platas-Iglesias C; Gale EM, Applications for transition-metal chemistry in contrast-enhanced magnetic resonance imaging. Inorg Chem 2020, 59 (10), 6648–6678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Snyder EM; Asik D; Abozeid SM; Burgio A; Bateman G; Turowski SG; Spernyak JA; Morrow JR, A Class of FeIII Macrocyclic Complexes with Alcohol Donor Groups as Effective T1 MRI Contrast Agents. Angew Chem Int Ed 2020, 132 (6), 2435–2440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wang H; Jordan VC; Ramsay IA; Sojoodi M; Fuchs BC; Tanabe KK; Caravan P; Gale EM, Molecular magnetic resonance imaging using a redox-active iron complex. J Am Chem Soc 2019, 141 (14), 5916–5925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kuźnik N; Wyskocka M, Iron (III) contrast agent candidates for MRI: a survey of the structure–effect relationship in the last 15 years of studies. Eur J Inorg Chem 2016, 2016 (4), 445–458. [Google Scholar]
  • 31.Boehm-Sturm P; Haeckel A; Hauptmann R; Mueller S; Kuhl CK; Schellenberger EA, Low-molecular-weight iron chelates may be an alternative to gadolinium-based contrast agents for T1-weighted contrast-enhanced MR imaging. Radiology 2018, 286 (2), 537–546. [DOI] [PubMed] [Google Scholar]
  • 32.Bales BC; Grimmond B; Johnson BF; Luttrell MT; Meyer DE; Polyanskaya T; Rishel MJ; Roberts J, Fe-HBED analogs: a promising class of iron-chelate contrast agents for magnetic resonance imaging. Contrast Media Mol I 2019, 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Xie J; Haeckel A; Hauptmann R; Ray IP; Limberg C; Kulak N; Hamm B; Schellenberger E, Iron (III)-t CDTA derivatives as MRI contrast agents: Increased T1 relaxivities at higher magnetic field strength and pH sensing. Magn Reson Med 2021, 85, 3370–3382. [DOI] [PubMed] [Google Scholar]
  • 34.Theil EC, Ferritin: The Protein Nanocage and Iron Biomineral in Health and in Disease. Inorg Chem 2013, 52 (21), 12223–12233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kosman DJ, Redox Cycling in Iron Uptake, Efflux, and Trafficking. J Biol Chem 2010, 285 (35), 26729–26735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Bealle G; Di Corato R; Kolosnjaj-Tabi J; Dupuis V; Clement O; Gazeau F; Wilhelm C; Menager C, Ultra Magnetic Liposomes for MR Imaging, Targeting, and Hyperthermia. Langmuir 2012, 28 (32), 11843–11851. [DOI] [PubMed] [Google Scholar]
  • 37.Malinge J; Geraudie B; Savel P; Nataf V; Prignon A; Provost C; Zhang YM; Ou P; Kerrou K; Talbot JN; Siaugue JM; Sollogoub M; Menager C, Liposomes for PET and MR Imaging and for Dual Targeting (Magnetic Field/Glucose Moiety): Synthesis, Properties, and in Vivo Studies. Mol Pharmaceut 2017, 14 (2), 406–414. [DOI] [PubMed] [Google Scholar]
  • 38.Lorenzato C; Oerlemans C; van Elk M; Geerts WJC; de Senneville BD; Moonen C; Bos C, MRI monitoring of nanocarrier accumulation and release using Gadolinium-SPIO co-labelled thermosensitive liposomes. Contrast Media Mol I 2016, 11 (3), 184–194. [DOI] [PubMed] [Google Scholar]
  • 39.Schwendener RA; Wuthrich R; Duewell S; Wehrli E; Vonschulthess GK, A Pharmacokinetic and Mri Study of Unilamellar Gadolinium-Dtpa-Stearate, Manganese-Dtpa-Stearate, and Iron-Dtpa-Stearate Liposomes as Organ-Specific Contrast Agents. Invest Radiol 1990, 25 (8), 922–932. [DOI] [PubMed] [Google Scholar]
  • 40.Affram K; Udofot O; Singh M; Krishnan S; Reams R; Rosenberg J; Agyare E, Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. Plos One 2017, 12 (9) e0185116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Asik D; Abozeid SM; Turowski SG; Spernyak JA; Morrow JR, Dinuclear Fe(III) Hydroxypropyl-Appended Macrocyclic Complexes as MRI Probes. Inorg Chem 2021, 60 (12), 8651–8664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Asik D; Smolinski R; Abozeid SM; Mitchell TB; Turowski SG; Spernyak JA; Morrow JR, Modulating the properties of Fe (III) macrocyclic MRI contrast agents by appending sulfonate or hydroxyl groups. Molecules 2020, 25 (10), 2291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Palagi L; Di Gregorio E; Costanzo D; Stefania R; Cavallotti C; Capozza M; Aime S; Gianolio E, Fe(deferasirox)2: An Iron(III)-Based Magnetic Resonance Imaging T1 Contrast Agent Endowed with Remarkable Molecular and Functional Characteristics. J Am Chem Soc 2021, 143 (35), 14178–14188. [DOI] [PubMed] [Google Scholar]
  • 44.Wang H; Wong A; Lewis LC; Nemeth GR; Jordan VC; Bacon JW; Caravan P; Shafaat HS; Gale EM, Rational Ligand Design Enables pH Control over Aqueous Iron Magnetostructural Dynamics and Relaxometric Properties. Inorg Chem 2020, 59 (23), 17712–17721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Baranyai Z; Carniato F; Nucera A; Horvath D; Tei L; Platas-Iglesias C; Botta M, Defining the conditions for the development of the emerging class of Fe(III)-based MRI contrast agents Chem. Sci 2021, 12, 11138–11145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Kras E; Abozeid SM; Eduardo W; Spernyak JA; Morrow JR, Comparison of phosphonate, hydroxypropyl and carboxylate pendants in Fe(III) macrocyclic complexes as MRI contrast agents. J. Inorg. Biochem 2021, 225, 111594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Patel A; Asik D; Snyder EM; Delillo AE; Cullen PJ; Morrow JR, Binding and release of Fe (III) complexes from glucan particles for delivery of T1 MRI contrast agents. Chemmedchem 2020, 15, 1050–57. [DOI] [PubMed] [Google Scholar]
  • 48.Schubert EM, Utilizing the Evans Method with a Superconducting Nmr Spectrometer in the Undergraduate Laboratory. J Chem Educ 1992, 69 (1), 62–62. [Google Scholar]
  • 49.Piguet C, Paramagnetic susceptibility by NMR: The “solvent correction” removed for large paramagnetic molecules. J Chem Educ 1997, 74 (7), 815–816. [Google Scholar]
  • 50.Silva BFB; Majzoub RN; Chan C-L; Li Y; Olsson U; Safinya CR, PEGylated cationic liposome-DNA complexation in brine is pathway-dependent. Biochim Biophys Acta 2014, 1838 (1 Pt B), 398–412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Mulder WJ; Strijkers GJ; Griffioen AW; van Bloois L; Molema G; Storm G; Koning GA; Nicolay K, A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem 2004, 15 (4), 799–806. [DOI] [PubMed] [Google Scholar]
  • 52.Kessel A; Ben-Tal N; May S, Interactions of cholesterol with lipid bilayers: the preferred configuration and fluctuations. Biophys J 2001, 81 (2), 643–58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Chahid B; Vander Elst L; Flament J; Boumezbeur F; Medina C; Port M; Muller RN; Lesieur S, Entrapment of a neutral Tm(III)-based complex with two inner-sphere coordinated water molecules into PEG-stabilized vesicles: towards an alternative strategy to develop high-performance LipoCEST contrast agents for MR imaging. Contrast Media Mol Imaging 2014, 9 (6), 391–9. [DOI] [PubMed] [Google Scholar]
  • 54.Ghaghada K; Hawley C; Kawaji K; Annapragada A; Mukundan S Jr., T1 relaxivity of core-encapsulated gadolinium liposomal contrast agents--effect of liposome size and internal gadolinium concentration. Acad Radiol 2008, 15 (10), 1259–63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Guenoun J; Doeswijk GN; Krestin GP; Bernsen MR, Compartmentalization of Gd liposomes: the quenching effect explained. Contrast Media Mol I 2016, 11 (2), 106–114. [DOI] [PubMed] [Google Scholar]
  • 56.Li Y; Xie Y; Wang Z; Zang N; Carniato F; Huang Y; Andolina CM; Parent LR; Ditri TB; Walter ED; Botta M; Rinehart JD; Gianneschi NC, Structure and Function of Iron-Loaded Synthetic Melanin. ACS Nano 2016, 10 (11), 10186–10194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Bertini I; Capozzi F; Luchinat C; Xia ZC, Nuclear and Electron Relaxation of Fe(OH2)63+. J Phys Chem 1993, 97 (6), 1134–1137. [Google Scholar]
  • 58.Pujales-Paradela R; Regueiro-Figueroa M; Esteban-Gómez D; Platas-Iglesias C, Transition Metal-based T1 Contrast Agents. In Contrast Agents for MRI: Experimental Methods, Pierre V; Allen M Eds. Royal Society: London, UK, 2018; pp 448–478. [Google Scholar]
  • 59.Terreno E; Delli Castelli D; Violante E; Sanders HM; Sommerdijk NA; Aime S, Osmotically shrunken LIPOCEST agents: an innovative class of magnetic resonance imaging contrast media based on chemical exchange saturation transfer. Chemistry 2009, 15 (6), 1440–8. [DOI] [PubMed] [Google Scholar]
  • 60.Zhao JM; Har-el YE; McMahon MT; Zhou J; Sherry AD; Sgouros G; Bulte JW; van Zijl PC, Size-induced enhancement of chemical exchange saturation transfer (CEST) contrast in liposomes. J Am Chem Soc 2008, 130 (15), 5178–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Terreno E; Barge A; Beltrami L; Cravotto G; Castelli DD; Fedeli F; Jebasingh B; Aime S, Highly shifted LIPOCEST agents based on the encapsulation of neutral polynuclear paramagnetic shift reagents. Chem Commun 2008, (5), 600–602. [DOI] [PubMed] [Google Scholar]
  • 62.Ferrauto G; Delli Castelli D; Di Gregorio E; Terreno E; Aime S, LipoCEST and cellCEST imaging agents: opportunities and challenges. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016, 8 (4), 602–18. [DOI] [PubMed] [Google Scholar]
  • 63.Terreno E; Boffa C; Menchise V; Fedeli F; Carrera C; Castelli DD; Digilio G; Aime S, Gadolinium-doped LipoCEST agents: a potential novel class of dual 1H-MRI probes. Chem Commun 2011, 47 (16), 4667–4669. [DOI] [PubMed] [Google Scholar]
  • 64.Aime S; Baroni S; Delli Castelli D; Brücher E; Fábián I; Serra SC; Fringuello Mingo A; Napolitano R; Lattuada L; Tedoldi F, Exploiting the Proton Exchange as an Additional Route to Enhance the Relaxivity of Paramagnetic MRI Contrast Agents. Inorg Chem 2018, 57 (9), 5567–5574. [DOI] [PubMed] [Google Scholar]
  • 65.Gianolio E; Porto S; Napolitano R; Baroni S; Giovenzana GB; Aime S, Relaxometric Investigations and MRI Evaluation of a Liposome-Loaded pH-Responsive Gadolinium(III) Complex. Inorg Chem 2012, 51 (13), 7210–7217. [DOI] [PubMed] [Google Scholar]
  • 66.Aime S; Botta M; Fasano M; Terreno E, Prototropic and water-exchange processes in aqueous solutions of Gd (III) chelates. Acc Chem Res 1999, 32 (11), 941–949. [Google Scholar]
  • 67.Gugliotta G; Botta M; Tei L, AAZTA-based bifunctional chelating agents for the synthesis of multimeric/dendrimeric MRI contrast agents. Org Biomol Chem 2010, 8 (20), 4569–4574. [DOI] [PubMed] [Google Scholar]
  • 68.Garello F; Terreno E, Sonosensitive MRI Nanosystems as Cancer Theranostics: A Recent Update. Front Chem 2018, 6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Laurent S; Vander Elst L; Thirifays C; Muller RN, Relaxivities of paramagnetic liposomes: on the importance of the chain type and the length of the amphiphilic complex. Eur Biophys J 2008, 37 (6), 1007–14. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material

RESOURCES